Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats
- 14 December 2008
- journal article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 600 (1-3), 93-97
- https://doi.org/10.1016/j.ejphar.2008.10.016
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive functionBiochemical Pharmacology, 2007
- Smoking and Schizophrenia: Is Symptom Profile Related to Smoking and which Antipsychotic Medication is of Benefit in Reducing Cigarette use?Australian & New Zealand Journal of Psychiatry, 2006
- In vitro regulation of serotonin transporter activity by protein kinase A and nicotinic acetylcholine receptors in the prefrontal cortex of ratsSynapse, 2006
- Ketanserin attenuates nicotine-induced working memory improvement in ratsPharmacology Biochemistry and Behavior, 2005
- Dopamine and drug addiction: the nucleus accumbens shell connectionNeuropharmacology, 2004
- Nicotinic–serotonergic interactions in brain and behaviourPharmacology Biochemistry and Behavior, 2002
- BLOCKAGE OF MOUSE MUSCLE NICOTINIC RECEPTORS BY SEROTONERGIC COMPOUNDSExperimental Physiology, 1999
- INFLUENCE OF α1‐ADRENOCEPTOR ANTAGONISM OF KETANSERIN ON THE NATURE OF ITS 5‐HT2 RECEPTOR ANTAGONISMClinical and Experimental Pharmacology and Physiology, 1994
- Understanding brain mechanisms in nicotine reinforcementBritish Journal of Addiction, 1991
- Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysisLife Sciences, 1990